Ethical Concerns About Relapse Studies
- 1 January 1996
- journal article
- Published by Cambridge University Press (CUP) in Cambridge Quarterly of Healthcare Ethics
- Vol. 5 (3) , 373-386
- https://doi.org/10.1017/s0963180100007180
Abstract
It is universally accepted that informed consent to participate in medical research should be given by subjects. People have the fundamental human right to freely choose, without coercion or withholding of information necessary to make a reasonable choice, whether they will undergo any risks associated with a research project. United States researchers have known for some time that they have the duty to inform potential subjects of the nature of proposed research and the risks and possible benefits, and to seek consent. Investigators also have the duty to design the research so that it will be scientifically valid while minimizing foreseeable and avoidable harms.Keywords
This publication has 43 references indexed in Scilit:
- Psychopharmacologic Treatment of SchizophreniaSchizophrenia Bulletin, 1993
- Clinical predictors of relapse following neuroleptic withdrawalBiological Psychiatry, 1992
- CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawalBiological Psychiatry, 1989
- L-dopa challenge and relapse in schizophreniaAmerican Journal of Psychiatry, 1987
- Does informed consent influence therapeutic outcome? A clinical trial of the hypnotic activity of placebo in patients admitted to hospital.BMJ, 1986
- Low-Dose Neuroleptic Treatment of Outpatient SchizophrenicsArchives of General Psychiatry, 1983
- Early Intervention, Time-limited, Targeted Pharmacotherapy of SchizophreniaSchizophrenia Bulletin, 1983
- Low dose fluphenazine decanoate in maintenance treatment of schizophreniaPsychiatry Research, 1979
- Long-Acting Oral vs Injectable Antipsychotic Drugs in SchizophrenicsArchives of General Psychiatry, 1978
- Overview: maintenance therapy in psychiatry: I. SchizophreniaAmerican Journal of Psychiatry, 1975